S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS

R. Andrew Shippy, Douglas Mendez, Kristina Jones, Irene Cergnul, Stephen E. Karpiak

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen. Methods: The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e. Results: Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments. Conclusions: SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.

Original languageEnglish (US)
Article number38
JournalBMC Psychiatry
Volume4
DOIs
StatePublished - Nov 11 2004
Externally publishedYes

Fingerprint

S-Adenosylmethionine
Acquired Immunodeficiency Syndrome
HIV
Depression
Therapeutics
Equipment and Supplies
Highly Active Antiretroviral Therapy
Major Depressive Disorder
Diagnostic and Statistical Manual of Mental Disorders
Population

ASJC Scopus subject areas

  • Medicine(all)
  • Psychiatry and Mental health

Cite this

S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. / Shippy, R. Andrew; Mendez, Douglas; Jones, Kristina; Cergnul, Irene; Karpiak, Stephen E.

In: BMC Psychiatry, Vol. 4, 38, 11.11.2004.

Research output: Contribution to journalArticle

Shippy, R. Andrew ; Mendez, Douglas ; Jones, Kristina ; Cergnul, Irene ; Karpiak, Stephen E. / S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. In: BMC Psychiatry. 2004 ; Vol. 4.
@article{04af2065c35c447b8f6d016a40522d04,
title = "S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS",
abstract = "Background: This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another {"}pill{"} or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen. Methods: The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e. Results: Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments. Conclusions: SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.",
author = "Shippy, {R. Andrew} and Douglas Mendez and Kristina Jones and Irene Cergnul and Karpiak, {Stephen E.}",
year = "2004",
month = "11",
day = "11",
doi = "10.1186/1471-244X-4-38",
language = "English (US)",
volume = "4",
journal = "BMC Psychiatry",
issn = "1471-244X",
publisher = "BioMed Central",

}

TY - JOUR

T1 - S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS

AU - Shippy, R. Andrew

AU - Mendez, Douglas

AU - Jones, Kristina

AU - Cergnul, Irene

AU - Karpiak, Stephen E.

PY - 2004/11/11

Y1 - 2004/11/11

N2 - Background: This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen. Methods: The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e. Results: Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments. Conclusions: SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.

AB - Background: This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen. Methods: The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e. Results: Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments. Conclusions: SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.

UR - http://www.scopus.com/inward/record.url?scp=12944262127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944262127&partnerID=8YFLogxK

U2 - 10.1186/1471-244X-4-38

DO - 10.1186/1471-244X-4-38

M3 - Article

VL - 4

JO - BMC Psychiatry

JF - BMC Psychiatry

SN - 1471-244X

M1 - 38

ER -